AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$54.53
-0.26 (-0.47%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$54.79
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
29,711

10-day average volume:
5,574,523
29,711

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Generac Holdings Inc. of Class Action Lawsuit and Upcoming Deadline - GNRC

8:54 pm ET October 15, 2021 (PR Newswire) Print

Pomerantz LLP announces that a class action lawsuit has been filed against Generac Holdings Inc. ("Generac" or the "Company") (NYSE: GNRC) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-07009, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired publicly traded Generac securities between February 23, 2021 and July 29, 2021, inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg

If you are a shareholder who purchased or otherwise acquired Generac securities during the Class Period, you have until October 19, 2021 to ask the Court to appoint you as Lead Plaintiff for the Class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Generac purports to be a leading global designer and manufacturer of a wide range of energy technology solutions, which provides power generation equipment and other power products serving the residential, light commercial and industrial markets.

The complaint alleges that, throughout the Class Period, statements made by Defendants were materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts about the Company's business, operational and financial results, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Generac's portable generators posed an unreasonable risk of injury to users and the public; (ii) as a result, at least seven finger amputations and one crushed finger had been reported to the Company; (iii) as a result, Generac would face increased regulatory scrutiny; (iv) the Company would end sales in its Generac(R) and DR(R) 6500 Watt and 8000 Watt portable generators in the U.S. and Canada in June 2021; (v) the Company would recall its Generac(R) and DR(R) 6500 Watt and 8000 Watt portable generators in the U.S. and Canada; (vi) the end of sales and the recall would occur before the Company's noted hurricane and wildfire seasons and following the Texas outage-periods the Company has touted for sales; and (vii) as a result, Defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.

On July 29, 2021, the U.S. Consumer Product Safety Commission, Health Canada, and the Organization for Economic Co-operation and Development announced the Generac portable generator recall, revealing that the Company had received reports of seven finger amputations and one finger crushing.

On this news, Generac's stock price fell $31.04 per share, or 7%, from its July 28, 2021 closing price over the next three trading days to close at $400.00 per share on August 2, 2021, damaging investors.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980

https://c212.net/c/img/favicon.png?sn=DC41966&sd=2021-10-15

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert--pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-generac-holdings-inc-of-class-action-lawsuit-and-upcoming-deadline--gnrc-301401637.html

SOURCE Pomerantz LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=DC41966&Transmission_Id=202110152054PR_NEWS_USPR_____DC41966&DateId=20211015

comtex tracking

COMTEX_395295364/1005/2021-10-15T20:54:09

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.